Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1991 Mar;31(3):350–352. doi: 10.1111/j.1365-2125.1991.tb05542.x

Limitation to the use of the urinary S-/R-mephenytoin ratio in pharmacogenetic studies.

Y Zhang 1, R A Blouin 1, P J McNamara 1, J Steinmetz 1, P J Wedlund 1
PMCID: PMC1368365  PMID: 2054275

Abstract

The reproducibility of the S-/R-mephenytoin ratio was examined in urines stored at -20 degrees C over 2 years. Large changes in this ratio were observed in some urine samples stored for only a few months under these conditions. The changes observed in the S-/R-mephenytoin ratio are attributed to the decomposition of an acid labile metabolite of S-mephenytoin which is eliminated in the urine. The instability of this metabolite makes it desirable to process urine shortly after its collection in order to avoid inaccurate phenotype assignments based upon the urinary S-/R-mephenytoin ratio. If rapid processing of urines is impractical, additional methods are described for preventing improper phenotype assignment of subjects.

Full text

PDF
352

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Drøhse A., Bathum L., Brøsen K., Gram L. F. Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark. Br J Clin Pharmacol. 1989 May;27(5):620–625. doi: 10.1111/j.1365-2125.1989.tb03426.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Guttendorf R. J., Britto M., Blouin R. A., Foster T. S., John W., Pittman K. A., Wedlund P. J. Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism. Br J Clin Pharmacol. 1990 Apr;29(4):373–380. doi: 10.1111/j.1365-2125.1990.tb03653.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Küpfer A., Desmond P., Patwardhan R., Schenker S., Branch R. A. Mephenytoin hydroxylation deficiency: kinetics after repeated doses. Clin Pharmacol Ther. 1984 Jan;35(1):33–39. doi: 10.1038/clpt.1984.5. [DOI] [PubMed] [Google Scholar]
  4. Meier U. T., Dayer P., Malè P. J., Kronbach T., Meyer U. A. Mephenytoin hydroxylation polymorphism: characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo. Clin Pharmacol Ther. 1985 Nov;38(5):488–494. doi: 10.1038/clpt.1985.213. [DOI] [PubMed] [Google Scholar]
  5. Nakamura K., Goto F., Ray W. A., McAllister C. B., Jacqz E., Wilkinson G. R., Branch R. A. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther. 1985 Oct;38(4):402–408. doi: 10.1038/clpt.1985.194. [DOI] [PubMed] [Google Scholar]
  6. Sanz E. J., Villén T., Alm C., Bertilsson L. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther. 1989 May;45(5):495–499. doi: 10.1038/clpt.1989.63. [DOI] [PubMed] [Google Scholar]
  7. Wedlund P. J., Aslanian W. S., Jacqz E., McAllister C. B., Branch R. A., Wilkinson G. R. Phenotypic differences in mephenytoin pharmacokinetics in normal subjects. J Pharmacol Exp Ther. 1985 Sep;234(3):662–669. [PubMed] [Google Scholar]
  8. Wedlund P. J., Aslanian W. S., McAllister C. B., Wilkinson G. R., Branch R. A. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther. 1984 Dec;36(6):773–780. doi: 10.1038/clpt.1984.256. [DOI] [PubMed] [Google Scholar]
  9. Wedlund P. J., Sweetman B. J., Wilkinson G. R., Branch R. A. Pharmacogenetic association between the formation of 4-hydroxymephenytoin and a new metabolite of S-mephenytoin in man. Drug Metab Dispos. 1987 Mar-Apr;15(2):277–279. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES